Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_4
1
20%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

recruiting120%
not_yet_recruiting120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruitingphase_4

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial

NCT07604311
recruiting

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

NCT07585981
completedphase_3

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
completedphase_3

Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

NCT05534919
completedphase_2

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

NCT01738035

Clinical Trials (5)

Showing 5 of 5 trials
NCT07604311Phase 4

Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial

Not Yet Recruiting
NCT07585981

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

Recruiting
NCT03643965Phase 3

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Completed
NCT05534919Phase 3

Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301

Completed
NCT01738035Phase 2

The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5